Drug intelligence / Profile preview

methylprednisolone + bupivacaine

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Subacromial Injection
01

Overview

methylprednisolone + bupivacaine is a combination drug product consisting of a synthetic glucocorticoid and a local anesthetic. In the context of clinical trials conducted by InGeneron, Inc., this specific combination (80 mg methylprednisolone and 0.25% bupivacaine) is utilized as the active control arm for treating symptomatic partial-thickness rotator cuff tears. Methylprednisolone serves as a potent anti-inflammatory agent that mediates its effects through the glucocorticoid receptor, reducing the production of inflammatory cytokines and mediators. Bupivacaine is a long-acting local anesthetic that blocks voltage-gated sodium channels, providing immediate but temporary pain relief. This combination represents the standard of care comparator against which InGeneron's investigational autologous adipose-derived regenerative cell (ADRC) therapy is being evaluated in a pivotal, randomized, double-blind trial.

Brand names
Depo-MedrolMarcaineSensorcaine
Other names
Corticosteroid controlMethylprednisolone and bupivacaine combinationCorticosteroid injection
02

Targets

OCT (Organic cation transporter family)NaV (Voltage-gated sodium channels)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on methylprednisolone + bupivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylprednisolone + bupivacaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call